Aulosirazole Stimulates FOXO3a Nuclear Translocation to Regulate Apoptosis and Cell-Cycle Progression in High-Grade Serous Ovarian Cancer (HGSOC) Cells.

IF 3.2 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Manead Khin, Lydia J Davis, Daniel D Lantvit, Jimmy Orjala, Joanna E Burdette
{"title":"Aulosirazole Stimulates FOXO3a Nuclear Translocation to Regulate Apoptosis and Cell-Cycle Progression in High-Grade Serous Ovarian Cancer (HGSOC) Cells.","authors":"Manead Khin, Lydia J Davis, Daniel D Lantvit, Jimmy Orjala, Joanna E Burdette","doi":"10.1124/molpharm.124.000921","DOIUrl":null,"url":null,"abstract":"<p><p>Ovarian cancer, the fifth leading cause of cancer-related mortality in women, is the most lethal gynecological malignancy globally. Within various ovarian cancer subtypes, high-grade serous ovarian cancer is the most prevalent and there is frequent emergence of chemoresistance. Aulosirazole, an isothiazolonaphthoquinone alkaloid, isolated from the cyanobacterium <i>Nostoc</i> sp. UIC 10771, demonstrated cytotoxic activity against OVCAR3 cells (IC<sub>50</sub> = 301 ± 80 nM). Using immunocytochemistry, OVCAR3 cells treated with aulosirazole demonstrated increased concentrations of phosphorylated protein kinase B and phosphorylated c-Jun N-terminal kinase with subsequent accumulation of forkhead box O3a (FOXO3a) in the nucleus. The combination of aulosirazole with protein kinase B inhibitors resulted in the most nuclear accumulation of FOXO3a aulosirazole-induced apoptosis based on cleavage of poly(ADP-ribose) polymerase, annexin V staining, and induction of caspase 3/7 activity in OVCAR3, OVCAR5, and OVCAR8. The expression of downstream targets of FOXO3a, including B-cell lymphoma 2 (BCL2) and p53-upregulator modulator of apoptosis, increased following aulosirazole treatment. Aulosirazole upregulated the FOXO3a target, cyclin-dependent kinase inhibitor 1, and increased cell-cycle arrest in the G0/G1 phase. The downregulation of FOXO3a by short hairpin RNA (shRNA) reduced the cytotoxicity after aulosirazole treatment by 3-fold IC<sub>50</sub> (949 ± 16 nM) and eliminated its ability to regulate downstream targets of FOXO3a. These findings underscore FOXO3a as a critical mediator of aulosirazole-induced cytotoxicity. Additionally, aulosirazole was able to decrease migration and invasion while increasing cell death in 3D tumor spheroids. However, in vivo OVCAR8 tumor burden was not reduced by aulosirazole using an intraperitoneal tumor model. Given the mechanism of action of aulosirazole, this class of alkaloids represents promising lead compounds to develop treatments against FOXO3a-downregulated cancers. SIGNIFICANCE STATEMENT: Aulosirazole, an isothiazolonaphthoquinone alkaloid, exhibits potent cytotoxic effects against high-grade serous ovarian cancer by promoting forkhead box O3a (FOXO3a) nuclear accumulation and modulating downstream targets. These findings highlight the potential of aulosirazole as a promising therapeutic intervention for cancers characterized by FOXO3a downregulation.</p>","PeriodicalId":18767,"journal":{"name":"Molecular Pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331498/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1124/molpharm.124.000921","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Ovarian cancer, the fifth leading cause of cancer-related mortality in women, is the most lethal gynecological malignancy globally. Within various ovarian cancer subtypes, high-grade serous ovarian cancer is the most prevalent and there is frequent emergence of chemoresistance. Aulosirazole, an isothiazolonaphthoquinone alkaloid, isolated from the cyanobacterium Nostoc sp. UIC 10771, demonstrated cytotoxic activity against OVCAR3 cells (IC50 = 301 ± 80 nM). Using immunocytochemistry, OVCAR3 cells treated with aulosirazole demonstrated increased concentrations of phosphorylated protein kinase B and phosphorylated c-Jun N-terminal kinase with subsequent accumulation of forkhead box O3a (FOXO3a) in the nucleus. The combination of aulosirazole with protein kinase B inhibitors resulted in the most nuclear accumulation of FOXO3a aulosirazole-induced apoptosis based on cleavage of poly(ADP-ribose) polymerase, annexin V staining, and induction of caspase 3/7 activity in OVCAR3, OVCAR5, and OVCAR8. The expression of downstream targets of FOXO3a, including B-cell lymphoma 2 (BCL2) and p53-upregulator modulator of apoptosis, increased following aulosirazole treatment. Aulosirazole upregulated the FOXO3a target, cyclin-dependent kinase inhibitor 1, and increased cell-cycle arrest in the G0/G1 phase. The downregulation of FOXO3a by short hairpin RNA (shRNA) reduced the cytotoxicity after aulosirazole treatment by 3-fold IC50 (949 ± 16 nM) and eliminated its ability to regulate downstream targets of FOXO3a. These findings underscore FOXO3a as a critical mediator of aulosirazole-induced cytotoxicity. Additionally, aulosirazole was able to decrease migration and invasion while increasing cell death in 3D tumor spheroids. However, in vivo OVCAR8 tumor burden was not reduced by aulosirazole using an intraperitoneal tumor model. Given the mechanism of action of aulosirazole, this class of alkaloids represents promising lead compounds to develop treatments against FOXO3a-downregulated cancers. SIGNIFICANCE STATEMENT: Aulosirazole, an isothiazolonaphthoquinone alkaloid, exhibits potent cytotoxic effects against high-grade serous ovarian cancer by promoting forkhead box O3a (FOXO3a) nuclear accumulation and modulating downstream targets. These findings highlight the potential of aulosirazole as a promising therapeutic intervention for cancers characterized by FOXO3a downregulation.

阿洛西拉唑刺激 FOXO3a 核转位以调控高级别浆液性卵巢癌(HGSOC)细胞的凋亡和细胞周期进展
卵巢癌是导致女性癌症相关死亡的第五大原因,也是全球致死率最高的妇科恶性肿瘤。在各种卵巢癌亚型中,高级别浆液性卵巢癌(HGSOC)发病率最高,而且经常出现化疗耐药性。从蓝藻 Nostoc sp. UIC 10771 中分离出的异噻唑萘醌生物碱 Aulosirazole 对 OVCAR3 细胞具有细胞毒活性(IC50 = 301 { 加减} 80 nM)。使用免疫细胞化学方法,用乌洛硅唑处理的 OVCAR3 细胞显示 pAKT 和 pJNK 浓度增加,随后 FOXO3a 在细胞核中聚集。在 OVCAR3、OVCAR5 和 OVCAR8 中,根据 PARP 的裂解、Annexin V 染色和 caspase 3/7 活性的诱导,郁环唑诱导细胞凋亡。FOXO3a 的下游靶标(包括 BCL2 和 PUMA)的表达在经由乌洛西拉唑处理后显著增加。阿洛西唑上调了FOXO3a的靶标p21,并增加了细胞周期在G0/G1期的停滞。通过 shRNA 下调 FOXO3a 可使阿洛西拉唑处理后的细胞毒性降低三倍 IC50(949{加减}16 nM),并消除其调节 FOXO3a 下游靶标的能力。这些发现强调了 FOXO3a 是阿洛西拉唑诱导细胞毒性的关键介质。此外,在三维肿瘤球体内,乌洛西拉唑能够减少迁移和侵袭,同时增加细胞死亡。然而,在腹腔肿瘤模型中,体内 OVCAR8 肿瘤负荷并没有因阿洛西拉唑而显著减少。鉴于乌洛西拉唑的作用机制,该类生物碱是开发治疗FOXO3a下调癌症的有前途的先导化合物。意义声明 乌洛色唑是一种异噻唑并萘醌类生物碱,通过促进 FOXO3a 核积累和调节下游靶点,对 HGSOC 具有强大的细胞毒性作用。这些研究结果突出表明,对于以 FOXO3a 下调为特征的癌症,乌洛石唑是一种很有潜力的治疗干预药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Pharmacology
Molecular Pharmacology 医学-药学
CiteScore
7.20
自引率
2.80%
发文量
50
审稿时长
3-6 weeks
期刊介绍: Molecular Pharmacology publishes findings derived from the application of innovative structural biology, biochemistry, biophysics, physiology, genetics, and molecular biology to basic pharmacological problems that provide mechanistic insights that are broadly important for the fields of pharmacology and toxicology. Relevant topics include: Molecular Signaling / Mechanism of Drug Action Chemical Biology / Drug Discovery Structure of Drug-Receptor Complex Systems Analysis of Drug Action Drug Transport / Metabolism
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信